Charles River Laboratories CRL Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Business | ||||||
| DSA | $596.92M+0.9% | $591.57M-1.5% | $600.69M-2.8% | $618.03M+4.3% | $592.61M-1.8% | |
| Manufacturing | $190.54M-3.0% | $196.4M+3.0% | $190.69M-5.0% | $200.84M+12.5% | $178.49M-8.4% | |
| RMS | $208.37M+1.0% | $206.26M-3.4% | $213.47M+0.1% | $213.27M+0.1% | $213.07M+4.3% | |
| Total by Business | ||||||
| DSA | $6.88M-49.2% | $13.53M+199% | $4.53M-71.8% | $16.08M-8.4% | $17.54M+15.2% | |
| Manufacturing | $462K-89.7% | $4.47M+69.5% | $2.64M-64.6% | $7.44M+101% | $3.71M+15.5% | |
| RMS | $17.63M+336% | $4.04M-30.6% | $5.82M-21.5% | $7.42M+421% | $1.42M-93.3% | |
| Cost of revenue (excluding amortization of intangible assets) by Business | ||||||
| DSA | $435.16M-0.2% | $435.86M+6.8% | $408.11M-3.3% | $421.91M+0.4% | $420.14M-6.8% | |
| Manufacturing | $112.04M+8.9% | $102.87M-6.4% | $109.94M-0.1% | $110.03M+2.8% | $107M-1.8% | |
| RMS | $153.96M+5.6% | $145.82M-1.5% | $148M+3.4% | $143.14M+2.8% | $139.3M-12.2% | |
| Operating Income (Loss) by Business | ||||||
| DSA | $103.88M+22.7% | $84.67M-31.2% | $123.15M+0.3% | $122.78M+30.7% | $93.95M+49.5% | |
| Manufacturing | $46.84M+121% | -$227.65M-670% | $39.93M+231% | $12.06M+240% | -$8.62M+95.3% | |
| RMS | $49.77M— | —— | $34.55M-3.4% | $35.79M-17.9% | $43.61M+217% | |
| Segment operating income | $200.49M— | —— | $197.63M+15.8% | $170.63M+32.3% | $128.94M— | |
| SG&A by Business | ||||||
| DSA | $47.52M-18.0% | $57.94M+3.0% | $56.27M-6.6% | $60.27M-7.7% | $65.29M-12.4% | |
| Manufacturing | $29.71M-31.1% | $43.1M+32.4% | $32.56M+0.4% | $32.42M-4.7% | $34.03M+1.9% | |
| RMS | $1.6M-93.4% | $24.02M-3.7% | $24.93M-12.1% | $28.37M+17.2% | $24.21M-7.0% | |
| Acquisitions by Business | ||||||
| DSA | $340.99M— | —— | —— | —— | —— | |
| Manufacturing | $0— | —— | —— | —— | —— | |
| RMS | $0— | —— | —— | —— | —— | |
| Goodwill, Gross by Business | ||||||
| DSA | $1.96B+16.7% | $1.68B— | —— | —— | —— | |
| Manufacturing | $570.46M-0.8% | $574.89M— | —— | —— | —— | |
| RMS | $511.1M+0.1% | $510.84M— | —— | —— | —— | |
| Foreign exchange by Business | ||||||
| DSA | -$14.38M-393% | $4.91M— | —— | $40.19M+406% | $7.94M+120% | |
| Manufacturing | -$4.43M-390% | $1.53M— | —— | $21.92M+115% | $10.18M+146% | |
| RMS | $257K-52.3% | $539K+299% | $135K-82.1% | $755K-94.0% | $12.68M+1,453% | |
| Goodwill, Written off Related to Sale of Business Unit by Business | ||||||
| DSA | $46.65M— | —— | —— | —— | $4M— | |
| Manufacturing | $0— | $0— | $0— | $0— | $0— | |
| RMS | $0— | $0— | $0— | $0— | $0— | |
| Capital Expenditures by Business | ||||||
| DSA | $37.51M-30.8% | $54.23M+111% | $25.71M+39.0% | $18.5M-46.4% | $34.52M-7.2% | |
| Manufacturing | $6.27M-19.5% | $7.8M+50.2% | $5.19M-53.5% | $11.16M-35.4% | $17.28M+67.4% | |
| RMS | $11.57M-53.2% | $24.74M+680% | $3.17M-12.8% | $3.64M-50.0% | $7.29M-73.6% | |
| D&A by Business | ||||||
| DSA | $39.91M-12.0% | $45.37M+3.1% | $44M+3.3% | $42.58M+1.2% | $42.08M-15.6% | |
| Manufacturing | $8.4M-34.8% | $12.88M-25.9% | $17.38M-68.6% | $55.34M+1.3% | $54.62M+83.4% | |
| RMS | $16.14M-8.6% | $17.67M-19.5% | $21.94M+11.3% | $19.71M-9.4% | $21.76M+4.8% | |
| Intangible Amortization by Business | ||||||
| DSA | $10.36M-20.9% | $13.11M-0.4% | $13.15M+0.6% | $13.07M-1.1% | $13.22M-14.1% | |
| Manufacturing | $1.95M-52.6% | $4.1M-50.4% | $8.27M-82.2% | $46.33M+0.6% | $46.08M+129% | |
| RMS | $3.04M-20.2% | $3.81M-36.4% | $5.98M0.0% | $5.98M+0.3% | $5.97M+4.1% | |
| Goodwill, impaired, accumulated impairment loss by Business | ||||||
| DSA | $1B0.0% | $1B0.0% | $1B0.0% | $1B0.0% | $1B0.0% | |
| Manufacturing | $380M0.0% | $380M+76.7% | $215M0.0% | $215M0.0% | $215M— | |
| Total Revenue by Geography | ||||||
| Asia Pacific | $55.48M-2.5% | $56.91M+10.2% | $51.66M-5.2% | $54.5M+29.9% | $41.94M-24.8% | |
| Canada | $109.57M-11.1% | $123.28M+5.5% | $116.81M-13.8% | $135.59M+8.2% | $125.35M+5.0% | |
| Europe | $277.58M-0.8% | $279.9M+0.8% | $277.69M-1.5% | $281.86M+7.1% | $263.25M0.0% | |
| Other | $9.4M-44.0% | $16.79M-20.4% | $21.08M+104% | $10.33M-38.0% | $16.67M-2.7% | |
| U.S. | $543.81M+5.1% | $517.35M-3.8% | $537.61M-2.2% | $549.86M+2.4% | $536.96M-1.8% | |
| Long-Lived Assets by Geography | ||||||
| Asia Pacific | $60.91M-1.5% | $61.81M+0.4% | $61.55M-4.1% | $64.18M-0.8% | $64.72M-2.0% | |
| Canada | $162.41M-0.6% | $163.34M+6.3% | $153.67M-1.9% | $156.58M+5.4% | $148.61M+1.1% | |
| Europe | $450.34M-3.9% | $468.64M+4.9% | $446.63M-1.2% | $452M+5.8% | $427.21M+3.4% | |
| Other | $42.48M+0.7% | $42.19M+3.5% | $40.79M+1.7% | $40.11M+5.7% | $37.96M+4.4% | |
| U.S. | $794.02M-13.6% | $919.24M+3.4% | $888.99M-0.5% | $893.87M-1.6% | $908.58M-3.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Charles River Laboratories break its business down?
- Charles River Laboratories (CRL) reports total revenue by business across 3 parts — DSA, Manufacturing and RMS. Each is extracted from the segment footnotes and tracked over time.
- Where does Charles River Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Charles River Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
